Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Chief Medical Officer | September 15, 2026 | September 15, 2026 |
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | CHIEF MEDICAL OFFICER | April 05, 2024 | April 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,771 |
Ending reported balance
After 2026-09-15 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 3,500 · Balance 36,218 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 3,500 · Balance 39,718 Row 3 · 2026-09-15 · Sale · Disposed 2,384 · Balance 37,334 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Row 4 · 2026-09-15 · Sale · Disposed 3,150 · Balance 34,184 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive. Row 5 · 2026-09-15 · Sale · Disposed 1,366 · Balance 32,818 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive. Row 6 · 2026-09-15 · Sale · Disposed 100 · Balance 32,718 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive. Row 7 · 2026-09-15 · Sale · Disposed 947 · Balance 31,771 F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.84 · Expires 2034-05-06 | Direct | 193,563 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 3,500 · Balance 193,563 F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
| Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14 | Direct | 164,992 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 3,500 · Balance 164,992 F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive.
F6: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
F7: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
F8: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Tvardi Therapeutics, Inc.
Report date April 05, 2024 · Filed April 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,365 |
Reported balance
After 2024-04-05 transaction · row 1
1 source rowRow 1 · 2024-04-05 · Sale · Disposed 2,753 · Balance 53,365 F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person on March 12, 2020 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2021 Filed Apr 1, 2021 23:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001209191-21-024296 · doc4.xml · derivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-03-30 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30,2021, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 23:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024296 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,610 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:55 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,000 | $19.65 | $58,950.00 |
DisclosureSEC source: 0001209191-21-022913 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,610 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019, as amended on August 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.36 to $19.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 22:45 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,093 | $17.98 | $55,612.14 |
DisclosureSEC source: 0001209191-21-018646 · doc4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,610 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:45 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018646 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,703 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 4, 2021. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 02:04 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 3,372 | $19.33 | $65,180.76 |
DisclosureSEC source: 0001209191-21-014548 · doc4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,703 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:04 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014548 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,075 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on February 23, 2021. The vested shares represents the last possible vesting event of the total number of shares subject to the award. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:02 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $19.73 | $39,460.00 |
DisclosureSEC source: 0001209191-21-013877 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,075 F1 · kind: This sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019, and amended on August 19, 2020. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 22:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $20.12 | $40,240.00 |
DisclosureSEC source: 0001209191-21-005146 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,075 F1 · kind: This sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019, and amended on August 19, 2020. Read SEC document |
| December 30, 2020 Filed Dec 30, 2020 23:14 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 1,298 | $15.30 | $19,859.40 |
DisclosureSEC source: 0001209191-20-065579 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,075 F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting of the RSUs reported on Form 4 filed with the Securities and Exchange Commission on December 29, 2020, and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (1). Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 23:43 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065408 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,373 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 23, 2020. The vested shares represents the third of four possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 21, 2020 Filed Dec 24, 2020 00:11 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $15.00 | $30,000.00 |
DisclosureSEC source: 0001209191-20-065107 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,373 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:48 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $15.31 | $30,620.00 |
DisclosureSEC source: 0001209191-20-060532 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,373 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person. Read SEC document |
| November 10, 2020 Filed Nov 13, 2020 22:39 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $15.00 | $30,000.00 |
DisclosureSEC source: 0001209191-20-058353 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,373 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 22:00 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 2,000 | $15.00 | $30,000.00 |
DisclosureSEC source: 0001209191-20-055597 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,373 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan, as amended, adopted by the Reporting Person. Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 22:00 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 10,627 | $15.20 | $161,530.40 |
DisclosureSEC source: 0001209191-20-036385 · doc4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,373 F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person. F3 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:00 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036385 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on June 10, 2020. Each RSU represents the contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001209191-20-013103 · doc4.xml · derivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2030-02-24 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 24, 2020, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 22:09 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-013103 · doc4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 24, 2021, February 24, 2022 and February 24, 2023, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 20:32 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $19.27 | $0.00 |
DisclosureSEC source: 0001209191-18-056060 · doc4.xml · derivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-10-22 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares shall vest and become exercisable on October 22, 2019; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from October 22, 2019, subject to the reporting person's continuous service with the issuer as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.